Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor

SCAI 2021 Late-breaking Clinical Study Results

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.


April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions Virtual Conference, which took place April 28 - May 1. Sessions share the latest advances in interventional cardiology and featured late-breaking clinical research. Find the entire virtual meeting program and links to the archived on-demand sessions at www.scai.org/scai2021.

SCAI 2021 Late-Breaking Studies:

Update on the North American COVID-19 Myocardial Infarction (NACMI) Registry — one-third of patients die, effects large percentage of minorities, 20% do not have cuplit lesions — Presented by Payam Dehghani, M.D., University of Saskatchewan

SCAI Shock Classification for Mortality Risk Stratification: Survey of Published Evidence. Presented by Jacob Jentzer, M.D., Mayo Clinic.

Final Results From The National Cardiogenic Shock Initiative — Survival With Impella Increased to 71%. Presented by Babar Basir, D.O., Henry Ford Health System.

Establishing the Optimal Duration of DAPT After PCI in High-Risk TWILIGHT-like patients with Acute Coronary Syndrome. Presented by Haoyu Wang, Fuwai Hospital, National Center for Cardiovascular Diseases

Study reveals need for equitable access of TAVR minimally invasive heart procedures. Presented by Ashwin Nathan, M.D., Hospital of the University of Pennsylvania

Study reveals patients in ISCHEMIA trial only represent small fraction of heart disease patients undergoing intervention, calling into question the study's application in real-world practice. Presented by Saurav Chatterjee, Northwell Health.

Safety and Efficacy of the Second Generation Robotic-Assisted System for Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION GRX Study in a real-world population across a spectrum of lesion complexity. Presented by Ehtisham Mahmud, M.D., UCS San Diego Health

Hospital-Level Percutaneous Coronary Intervention Performance with Simulated Risk Avoidance Strategies Did Not Necessarily Help Hospital Performance Scores. Presented by Ashwin Nathan, M.D., Hospital of the University of Pennsylvania

Radial Hemostasis Time Cut by 50 Percent With StatSeal in Combination With TR Band —reduces time to hemostasis following cardiac catheterization procedures and improves cath lab efficiency. Presented by Arnold Seto, M.D., UCI Health.

Breakthrough technology provides advanced, non-invasive treatment option for patients with congenital heart disease — One-year Results of the Harmony Transcatheter Pulmonary Valve Trial . Presented by Thomas Jones, M.D., Seattle Children’s Hospital

Global registry Shows Longer Stent Minimizes Procedure Complications in Sinus Venosus Atrial Septal Defects. Presented by Dr. Eric Rosenthal, Guy’s and St. Thomas NHS Foundation Trust in London, England

 

Other SCAI 202I News:

VIDEO: The Impact of COVID-19 on Heart Attack Patients — Interview with Payam Dehghani, M.D.

SCAI Updates Best Practices in the Cardiac Cath Lab Guidelines Document

VIDEO: Radial Hemostasis Reduced by 50 Percent With StatSeal in Combination With TR Band — Interview with Arnold Seto, M.D., and Jordan Safirstein, M.D

VIDEO: Harmony Transcatheter Pulmonary Valve Has Good Outcomes at 1 Year — Interview with Tom Jones, M.D.

Young African Americans With Coronary Disease Impacted by Non-traditional Risk Factors

VIDEO: Socioeconomic and Geographic Access to TAVR Programs is Limited — Interview with Ashwin Nathan M.D.

VIDEO: Final Results of the National Cardiogenic Shock Initiative Show 71 Percent Survival — Interview with Bill O'Neill, M.D.

VIDEO: Avoiding Higher Risk Cath Lab Patients May Not Improve Outcomes Scores — Interview with Ashwin Nathan M.D., 

Find more SCAI news and video

 

Related Late-Breaking Cardiology Presentations:

ACC 2021 Late-Breaking Presentations Announced

SCAI Announces 2020 Late-breaking Clinical Studies

 

TCT 2020 Late-breaking Study Presentations

American Heart Association 2020 Late-breaking Trial Presentations 

 

 

#SCAI2021


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now